BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Do insiders & institutionals hold more shares of BNTX or GSK?

15.5% of BioNTech shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, BNTX or GSK?

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Does the media refer more to BNTX or GSK?

In the previous week, GSK had 14 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for GSK and 1 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate BNTX or GSK?

BioNTech currently has a consensus target price of $137.86, suggesting a potential upside of 25.27%. GSK has a consensus target price of $37.38, suggesting a potential downside of 2.19%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.10

Is BNTX or GSK more profitable?

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-27.37%	-3.94%	-3.41%
GSK	9.89%	48.82%	11.15%

Which has better earnings and valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.98B	8.89	-$719.92M	-$3.40	-32.37
GSK	$40.10B	1.95	$3.29B	$1.94	19.70

Summary

GSK beats BioNTech on 10 of the 16 factors compared between the two stocks.